Ureteral cancer has a special anatomical site, which is connected to the kidney and renal pelvis at the upper end and to the bladder at the lower end. Therefore, when the surgical treatment of ureteral cancer is over, its chemotherapy includes two parts, namely systemic intravenous chemotherapy and bladder infusion chemotherapy. The purpose of bladder infusion chemotherapy is to maximize the concentration of chemotherapeutic drugs in the bladder to directly kill the malignant tumors potentially implanted in the bladder mucosa by means of bladder infusion chemotherapy, and the purpose of systemic chemotherapy is to prevent the occurrence of systemic and local metastasis of tumor cells. For chemotherapy regimen selection mainly includes anthracyclines such as epirubicin, metabolic drugs such as gemcitabine, hydroxycamptothecin, and some patients can also use platinum drugs in combination with chemotherapy, in any case platinum drug use, gemcitabine use is currently the basic drug for ureteral cancer.